ArticleJAMA oncology2023

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.

Mark A Socinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.